Investors put €10m into new fast and low-cost Dx tech
This article was originally published in Clinica
Biocartis, a Swiss start-up developing a novel diagnostics platform for low to highly multiplexed bioanalyte detection, has raised €10m ($14.9m) in a series A financing round. The funds were provided by a syndicate of investors, which was led by Aescap Venture and included Biovest, KBC Private Equity, Advent Venture Partners and existing Biocartis shareholder Benaruca. The proceeds will enable Lausanne-based Biocartis to develop a commercial version of its proprietary platform technology and first prototype assays. The company's focus is on bringing to market a versatile, compact diagnostics system that can be used across a wide range of settings and "drastically" reduce the time and costs of testing.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.